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We appreciate the interest and comments on our study, “The 
effect of an angiotensin receptor blocker on arterial stiffness in 
type 2 diabetes mellitus patients with hypertension,” which was 
published in Diabetes & Metabolism Journal 2011;35:236-242. 
  Hypertension and type 2 diabetes mellitus are major risk 
factors for cardiovascular disease. In type 2 diabetes, hyper-
tension often initiates and accelerates the progression of mac-
rovascular events by increasing arterial stiffness [1,2]. Increased 
arterial stiffness was recently reported to be a powerful and in-
dependent risk factor for early mortality and had more clinical 
prognostic value than previously identified cardiovascular dis-
ease risk factors such as age, gender, smoking and dyslipidemia 
[3].
  Previous studies have reported that angiotensin II type 1 re-
ceptor blockers reduce arterial stiffness [4-6]. In our study we 
assessed changes in central aortic waveforms and pulse wave 
velocity (PWV) as well as related parameters after treatment 
with valsartan in patients with type 2 diabetes and hyperten-
sion. We excluded patients concomitantly using insulin, thia-
zolidinedion or metformin as insulin resistance is associated 
with arterial stiffness and premature vascular sclerosis [7,8]. 
Our group of study subjects was homogeneous in terms of di-
abetes treatment, which had a minimal effect on insulin resis-
tance. 
  As Dr. Kim noted, our study has some limitations. There was 
no control group treated with other anti-hypertensive agents 
and confounding factors, such as lipid-lowering drugs, anti-
platelet agents, and smoking, were not considered in the anal-
ysis. We were unable to measure PWV in all participants and 
the potential selection bias and diminished statistical power 
due to the small number of subjects was another limitation of 
this study. 
  Although data was not shown in the article, there was no 
difference in baseline PWV values between the ‘PWV decrease’ 
and ‘no PWV decrease’ groups (11.0±1.8 vs. 10.5±2.0, P=
0.297), and baseline PWV values were not associated with fast-
ing blood glucose or HbA1c (P=0.462, P=0.641). We thought 
that if the number of subjects were larger, there might be asso-
ciation between them. Because there have been reported that 
fasting glucose and HbA1c were associated with PWV in type 
2 diabetes patients with hypertension [9]. In our results, the 
baseline glucose level was significantly higher in ‘no PWV de-
crease group.’ Therefore, we concluded that the change in PWV 
was associated with baseline glycemic control status. Also, there 
were no differences between the two groups in terms of systol-
ic or diastolic blood pressure at 12 weeks (P=0.183, P=0.396) 
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or drug compliance, which was verified at every patient visit. 
Thus a difference in blood pressure control was excluded as a 
factor influencing the difference in PWV between the two 
groups.
  The results of our study suggested that the angiotensin re-
ceptor blocker, valsartan, had a modest beneficial effect in re-
ducing arterial stiffness measured as PWV and the augmenta-
tion index in patients with type 2 diabetes and hypertension. 
Fasting glucose and HbA1c levels are likely to be independent-
ly associated with PWV improvement as a result of valsartan 
treatment. In future, further trials are needed to validate the 
effect observed in our study, to examine its stability over lon-
ger periods of follow-up, and to compare it with that obtained 
with other antihypertensive agents commonly used in clinical 
practice, and evaluate the pathogenic mechanism.
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